Emerging biomarkers in autism spectrum disorder: a systematic review
Frye RE, Vassall S, Kaur G, Lewis C, Karim M, Rossignol D. Emerging biomarkers in autism spectrum disorder: a systematic review. Ann Transl Med. 2019 Dec;7(23):792. doi: 10.21037/atm.2019.11.53. PMID: 32042808; PMCID: PMC6989979.
Physiological mediators of prenatal environmental influences in autism spectrum disorder
Frye RE, Cakir J, Rose S, Palmer RF, Austin C, Curtin P. Physiological mediators of prenatal environmental influences in autism spectrum disorder. Bioessays. 2021 Sep;43(9):e2000307. doi: 10.1002/bies.202000307. Epub 2021 Jul 14. PMID: 34260745.
A Systematic Review and Meta-Analysis of Immunoglobulin G Abnormalities and the Therapeutic Use of Intravenous Immunoglobulins (IVIG) in Autism Spectrum Disorder
Rossignol DA, Frye RE. A Systematic Review and Meta-Analysis of Immunoglobulin G Abnormalities and the Therapeutic Use of Intravenous Immunoglobulins (IVIG) in Autism Spectrum Disorder. J Pers Med. 2021 May 30;11(6):488. doi: 10.3390/jpm11060488. PMID: 34070826; PMCID: PMC8229039.
The Effectiveness of Cobalamin (B12) Treatment for Autism Spectrum Disorder: A Systematic Review and Meta-Analysis
Rossignol DA, Frye RE. The Effectiveness of Cobalamin (B12) Treatment for Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. J Pers Med. 2021 Aug 11;11(8):784. doi: 10.3390/jpm11080784. PMID: 34442428; PMCID: PMC8400809.
A Personalized Multidisciplinary Approach to Evaluating and Treating Autism Spectrum Disorder
Frye RE. A Personalized Multidisciplinary Approach to Evaluating and Treating Autism Spectrum Disorder. J Pers Med. 2022 Mar 14;12(3):464. doi: 10.3390/jpm12030464. PMID: 35330464; PMCID: PMC8949394.
Modern Biomarkers for Autism Spectrum Disorder: Future Directions
Jensen AR, Lane AL, Werner BA, McLees SE, Fletcher TS, Frye RE. Modern Biomarkers for Autism Spectrum Disorder: Future Directions. Mol Diagn Ther. 2022 Sep;26(5):483-495. doi: 10.1007/s40291-022-00600-7. Epub 2022 Jun 27. PMID: 35759118; PMCID: PMC9411091.
The Soluble Folate Receptor in Autism Spectrum Disorder: Relation to Autism Severity and Leucovorin Treatment.
Frye RE, Lane A, Worner A, Werner BA, McCarty PJ, Scheck AC, Collins HL, Adelman SJ, Quadros EV, Rossignol DA. The Soluble Folate Receptor in Autism Spectrum Disorder: Relation to Autism Severity and Leucovorin Treatment. J Pers Med. 2022 Dec 8;12(12):2033. doi: 10.3390/jpm12122033. PMID: 36556254; PMCID: PMC9786140.
Folate Receptor Alpha Autoantibodies in the Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) Population
Wells, L.; O’Hara, N.; Frye, R.E.; Hullavard, N.; Smith, E. J. Pers. Med. 2024, 14, 166.
TACA provides education, support, and hope to families living with autism. Thank you for your support.
Today’s complex disorders (Autism, Lyme, PANS, COVID etc) require a new understanding of the role inflammation, toxins, mitochondrial dysfunction etc are playing. Today’s patients need physicians to obtain new strategies, new diagnostic tools, & new perspectives. MAPS delivers these from leading clinicians & researchers. MAPS takes today’s complex health issues & provides a comprehensive path for clinicians to follow for successful outcomes. MAPS teaches tomorrow’s medicine today. Be part of the future – attend MAPS!
